echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > ​The world's first!

    ​The world's first!

    • Last Update: 2022-06-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    April 17, 2022/eMedClub News/--On March 31, 2022, the clinical trial application of the innovative drug ARB202 developed by ARBELE, a biotechnology company in Hong Kong Science Park, was approved by the Australian TGA.
    For the treatment of advanced gastrointestinal malignancies

    .
    This is the only CDH17xCD3 double anti-specific antibody approved for clinical use in the world

    .

    About ARB202

    About ARB202

    ARB202 is a First-in-Class bispecific antibody that targets gastrointestinal antigen CDH17 and T-cell CD3, developed based on Abella Pharma's unique and innovative CDH17 target
    .
    ARB202 has a unique affinity for anti-CDH17 and anti-CD3 differentiated structures.
    While ensuring high specificity and high killing activity, it avoids the risk of systemic immune response caused by excessive activation of T cells, so it has good safety and pharmacokinetics.
    Features and developability

    .

    Preclinical results showed that ARB202 effectively enhanced the interaction between T cells and CDH17-expressing gastrointestinal tumor cell lines, resulting in the activation of T cells and the release of IL-2, which effectively produced tumor cell killing
    .
    In vivo injection of low-dose ARB202 antibody can effectively inhibit tumor growth

    .

    At present, ARB202 has been officially approved by the Australian TGA to start a phase I clinical trial.
    The indication is for advanced gastrointestinal malignant tumors.
    Patient screening will continue in Hong Kong from this fall.
    (FDA) clinical trials

    .

    About ARBELE

    About ARBELE

    Founded in 2016, Abella Biopharma is focused on inventing and developing breakthrough and innovative immunotherapies, providing first-in-class cancer drugs and high-quality diagnostic screening platforms for early disease intervention
    .
    Abel is founded by senior drug R&D experts and executives who have worked for Johnson & Johnson, Roche, Sanofi and Bristol-Myers Squibb.
    The team of scientists comes from Cambridge, Oxford, Harvard, and Hong Kong University.
    Headquartered in Hong Kong, in Guangzhou, Seattle and Sydney have research and business units targeting high-mortality cancers such as stomach, pancreatic, colon, bile duct and liver cancers for which there are few current treatments

    .
    For more information on Arbelebio, please visit: https://

    ▲Hong Kong Science & Technology Park Campus 

    ▲Hong Kong Science & Technology Park Campus 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.